Novo Nordisk has partnered with Anthropic to accelerate its drug discovery and development processes. The collaboration utilizes the Claude AI model to address scientific challenges and enhance R&D software. This initiative supports the company’s ambition to lead in AI-driven healthcare.
Novo Nordisk will also present new cardiometabolic data at the European Association for the Study of Diabetes (EASD) 2026 meeting. Presentations include real-world evidence for the oral Wegovy® pill and updates on pipeline treatments like CagriSema. These insights cover obesity, type 2 diabetes, and related cardiovascular and kidney diseases.